When Orexigen Therapeutics' obesity drug, Contrave (now called NB32), was turned down by the Food and Drug Administration in January 2011, it looked like the company could fall to a distant third behind competitors Vivus and Arena. Now, an FDA decision on Contrave is expected by Wednesday, and analysts say its third-place arrival on the market may actually work in its favor.
Orexigen was required to start a multiyear study on the cardiovascular safety of its medicine before reapplying for FDA approval. Meanwhile, Vivus and Arena secured clearance of their drugs, Qsymia and Belviq, in 2012. (They have to do post-marketing studies to monitor safety.)
Help employers find you! Check out all the jobs and post your resume.
